Materiały źródłowe

• #1 Multiple Endocrine Neoplasias Type 2 – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK519054/

  Multiple endocrine neoplasia type 2 (MEN 2) is a hereditary cancer syndrome associated primarily with tumors of the adrenal gland, thyroid and parathyroid. […] This activity describes the evaluation and management of multiple endocrine neoplasia type 2 and reviews the role of the interprofessional team in improving care for patients with this condition. […] Review the use of total prophylactic thyroidectomy and lymph node dissection in the management of multiple endocrine neoplasia type 2. […] Summarize the importance of collaboration and communication among the interprofessional team to provide counseling and genetic testing to first degree relatives of those affected with multiple endocrine neoplasia type 2. […] As 25% of the patients diagnosed with Medullary thyroid cancer (MTC) have underlying RET proto-oncogene mutations, it is pertinent to screen for genetic mutations and other associated common tumors with the help of biochemical and radiological screening.

• #2 Multiple Endocrine Neoplasia Type 2 – Endocrine Surgery | UCLA Health

  https://www.uclahealth.org/medical-services/surgery/endocrine-surgery/patient-resources/patient-education/endocrine-surgery-encyclopedia/multiple-endocrine-neoplasia-type-2

  Definition: Multiple Endocrine Neoplasia II (MEN II) is a hereditary disorder in which a type of thyroid cancer accompanied by recurring cancer of the adrenal glands. […] One type of this disease (MEN IIa) is also associated with overgrowth (hyperplasia) of the parathyroid gland. […] The cause of MEN II is genetic — a mutation in a gene called RET. Multiple tumors may appear in the same person, but not necessarily at the same time. The adrenal tumor is a pheochromocytoma and the thyroid tumor is a medullary carcinoma of the thyroid. […] The disorder may occur at any age, and affects men and women equally. The main risk factor is a family history of MEN II. […] The symptoms may vary, but are consistent with those of pheochromocytoma, medullary carcinoma of the thyroid, and sometimes hyperparathyroidism.

• #3 Multiple Endocrine Neoplasia Type 2 | Children’s Hospital of Philadelphia

  https://www.chop.edu/conditions-diseases/multiple-endocrine-neoplasia-type-2

  MEN2 is a hereditary cancer syndrome, affecting approximately 1 in 35,000 people. […] It is important to identify this hereditary cancer syndrome early, as it often confers a high risk of tumors, which may occur at a younger-than-expected age. […] Evaluation by a specialist is necessary for accurate diagnosis and treatment, including knowing when to screen and when to consider surgical treatment. […] Although there is no cure for MEN2, there are options to minimize symptoms and decrease your child’s risk of certain cancers. Early and regular screening is the most important path to allow MEN2 patients to lead happy, productive and healthy lives. […] Treatment often includes: Tumor removal, Medication. […] Since there is a high risk for individuals with MEN2 to develop MTC, and MTC is an aggressive type of thyroid cancer, preventative removal of the thyroid gland (thyroidectomy) is generally recommended for individuals with MEN2.

• #4 Multiple Endocrine Neoplasia Type 2 (MEN2) (PDQ®) – NCI

  https://www.cancer.gov/publications/pdq/information-summaries/genetics/men2-hp-pdq

  MEN2 is caused by pathogenic variants in the RET gene. MEN2 is distinct from two similarly named syndromes, Multiple Endocrine Neoplasia Type 1 (MEN1) and Multiple Endocrine Neoplasia Type 4 (MEN4). The endocrine disorders observed in MEN2 are medullary thyroid cancer (MTC); its precursor, C-cell hyperplasia (CCH); pheochromocytoma (PHEO); and parathyroid adenomas and/or hyperplasia. […] The understanding of MEN2’s natural history continues to evolve. Clinical observations suggest that the natural history of MEN2 (particularly the penetrance of MTC) is variable. The manifestations of MEN2 could be subject to modifying effects from specific RET pathogenic variants, other genes, behavioral factors, or environmental exposures. […] Current stratification has moved away from a solely phenotype-based classification to one that is based on genotype (i.e., the pathogenic variant) and phenotype.

• #5 Multiple Endocrine Neoplasia | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/multiple-endocrine-neoplasia.html

  Multiple endocrine neoplasia type 2 (MEN2) is divided into three types: MEN2A, MEN2B, and Familial Medullary Thyroid Carcinoma (FMTC). […] People with multiple endocrine neoplasia type 2 (MEN2) have a 95% chance of developing medullary thyroid cancer. […] Genetic testing of blood samples can confirm a diagnosis of MEN2 and identify family members at risk of developing the disease. […] General recommendations are to remove the thyroid gland: Within the first six months of life for individuals with MEN2B; By five to 10 years of age for individuals with MEN2A and FMTC. […] If detected early, pheochromocytomas are easily treated. However, if not treated, they may be potentially fatal due to dangerously high blood pressures that can occur during accidents, surgery, childbirth or other physically stressful situations.

• #6 Multiple endocrine neoplasia type 2: An overview | Genetics in Medicine

  https://www.nature.com/articles/gim2011127

  The identification and phenotypic characterization of germline high-penetrance gain-of-function mutations in the RET proto-oncogene, encoding a receptor tyrosine kinase, as causing the great majority of multiple endocrine neoplasia (MEN) type 2 (MEN 2) heralded the era of accurate, evidence-based molecular diagnosis, predictive testing, genetic counseling, gene-informed cancer risk assessment, and preventative medicine. MEN 2, occurring in 1:200,000 live births, is an autosomal dominant neuroendocrine neoplasia predisposition syndrome characterized by variable penetrance of medullary thyroid carcinoma (MTC), pheochromocytoma, and hyperparathyroidism (HPT). […] MEN 2A makes up approximately 70-80% of cases of MEN 2. As genetic testing for RET mutations has become available, it has become apparent that 70-95% of individuals with MEN 2A develop MTC, approximately 50% develop pheochromocytoma, and approximately 15-30% develop HPT. MTC is generally the first manifestation of MEN 2A. Probands with MTC typically present with a neck mass or neck pain, usually before age 35 years.

• #7 Multiple Endocrine Neoplasias Type 2 – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK519054/

  Multiple endocrine neoplasia type 2 (MEN 2) is a hereditary cancer syndrome associated primarily with tumors of the adrenal gland, thyroid and parathyroid. […] This activity describes the evaluation and management of multiple endocrine neoplasia type 2 and reviews the role of the interprofessional team in improving care for patients with this condition. […] Review the use of total prophylactic thyroidectomy and lymph node dissection in the management of multiple endocrine neoplasia type 2. […] Summarize the importance of collaboration and communication among the interprofessional team to provide counseling and genetic testing to first degree relatives of those affected with multiple endocrine neoplasia type 2. […] As 25% of the patients diagnosed with Medullary thyroid cancer (MTC) have underlying RET proto-oncogene mutations, it is pertinent to screen for genetic mutations and other associated common tumors with the help of biochemical and radiological screening.

• #8 Multiple endocrine neoplasia type 2B

  https://dermnetnz.org/topics/multiple-endocrine-neoplasia-type-2b

  Multiple endocrine neoplasia type 2B disease has additional features including mucosal neuromas (nerve tumours on the mucous membranes), neuromas in the gut that lead to gastrointestinal abnormalities, and striking facial appearance associated with Marfanoid habitus (slender, tall, long fingers and toes, and high arched palate like Marfan disease). These features may be the first sign of an internal malignancy and should prompt further investigation. […] Like MEN type 2A disease, MEN type 2B disease carries a high risk for development of medullary carcinoma of the thyroid and phaeochromocytoma (a vascular tumour of the adrenal gland that may cause high blood pressure). […] Individuals with MEN type 2B disease should have their thyroid gland removed at a very early age (around 1 year) to reduce the risk of thyroid cancer. Compared with other types of thyroid cancer, medullary carcinoma of the thyroid is a very aggressive cancer. If the thyroid is not removed in childhood, the average age of death in people with MEN type 2B disease is around 21 years. Once the thyroid is removed, patients must take thyroid hormone replacements (thyroxine) for the rest of their life.

• #9 Multiple endocrine neoplasia: MedlinePlus GeneticsLock

  https://medlineplus.gov/genetics/condition/multiple-endocrine-neoplasia/

  Multiple endocrine neoplasia type 2 is divided into three subtypes: type 2A, type 2B (formerly called type 3), and familial medullary thyroid carcinoma (FMTC). […] The most common sign of multiple endocrine neoplasia type 2 is a form of thyroid cancer called medullary thyroid carcinoma. […] Some people with this disorder also develop a pheochromocytoma, which is an adrenal gland tumor that can cause dangerously high blood pressure. […] The signs and symptoms of multiple endocrine neoplasia type 2 are relatively consistent within any one family. […] Multiple endocrine neoplasia type 2 and type 4 are also inherited in an autosomal dominant pattern. […] Affected individuals often inherit an altered RET or CDKN1B gene from one parent with the condition.

• #10 Multiple Endocrine Neoplasia Type 2 (MEN2) (PDQ®) – NCI

  https://www.cancer.gov/publications/pdq/information-summaries/genetics/men2-hp-pdq

  Diagnosis of the two MEN2 clinical subtypes relies on a combination of clinical findings, family history, and molecular genetic testing of the RET gene. […] Most patients with MEN2 have the MEN2A subtype. […] MEN2A is diagnosed clinically by the occurrence of two specific endocrine tumors in addition to MTC: PHEO and/or parathyroid adenoma and/or hyperplasia in a single individual or in close relatives. […] The standard treatment for adults with MTC is surgical removal of the entire thyroid gland, including the posterior capsule and central lymph node dissection. […] Risk-reducing thyroidectomy (also referred to as early thyroidectomy and previously referred to as prophylactic thyroidectomy) is the oncological treatment of choice for patients with MEN2. […] For patients with RET germline variants, older age at risk-reducing thyroidectomy has been significantly associated with a higher risk of persistent or recurrent disease.

• #11 Multiple Endocrine Neoplasia Type 2 – Endocrine Surgery | UCLA Health

  https://www.uclahealth.org/medical-services/surgery/endocrine-surgery/patient-resources/patient-education/endocrine-surgery-encyclopedia/multiple-endocrine-neoplasia-type-2

  Diagnosis depends on identification of mutation of the RET gene. This can be done with a blood test. […] Surgery is needed to remove both the medullary carcinoma of the thyroid and the pheochromocytoma. Medullary carcinoma of the thyroid must be treated with total removal of the thyroid gland and removal of surrounding lymph nodes. Hormone replacement therapy is given after surgery. […] Family members should be screened for the RET gene mutation. […] Pheochromocytoma is usually benign (not cancer), but the accompanying medullary carcinoma of the thyroid that characterizes this condition is a very aggressive and potentially fatal cancer. Nonetheless, early diagnosis and surgery can often lead to cure. […] Screening of close relatives of a person with MEN II may lead to early detection.

• #12 Multiple endocrine neoplasia (MEN) II Information | Mount Sinai – New York

  https://www.mountsinai.org/health-library/diseases-conditions/multiple-endocrine-neoplasia-men-ii

  Multiple endocrine neoplasia, type II (MEN II) is a disorder passed down through families in which one or more of the endocrine glands are overactive or form a tumor. […] To diagnose this condition, the health care provider looks for a mutation in the RET gene. This can be done with a blood test. Additional tests are done to determine which hormones are being overproduced. […] Surgery is needed to remove a pheochromocytoma, which can be life threatening due to the hormones it makes. […] If a child is known to carry the RET gene mutation, surgery to remove the thyroid before it becomes cancerous is considered. This should be discussed with a physician who is very familiar with this condition. […] Contact your provider if you notice symptoms of MEN II or if someone in your family receives such a diagnosis. […] Screening close relatives of people with MEN II may lead to early detection of the syndrome and related cancers. This may allow for steps to prevent complications.

• #13 Multiple Endocrine Neoplasia Type 2 (MEN2) Guidelines: Guidelines Summary, Pheochromocytoma, Parathyroid Disease

  https://emedicine.medscape.com/article/123447-guidelines

  In 2015, the American Thyroid Association (ATA) published revised guidelines for the diagnosis and treatment of medullary thyroid carcinoma (MTC) that included recommendations for management of multiple endocrine neoplasia type 2 (MEN2). The National Comprehensive Cancer Network (NCCN) includes recommendations for diagnosis and treatment of MEN2 in its guidelines for thyroid cancer and its guideline for neuroendocrine and adrenal tumors. […] According to NCCN guidelines, the criterion for a clinical diagnosis of MEN2A is two or more MEN2A-associated tumors (medullary thyroid carcinoma [MTC], adrenal pheochromocytoma) in an individual or in a first-degree relative. Other physical findings include lichen planus amyloidosis and Hirschsprung disease. […] NCCN guidelines recommend offering a MEN2 clinical evaluation to individuals with a clinical diagnosis or suspicion of MEN2, even those with a negative RET genetic test. At-risk relatives should also be offered evaluation even if RET mutation has not been identified or if RET genetic testing has not been performed in the affected family member. Clinical evaluation should include the following tests: Biochemical tests of hormone levels, Imaging tests to localize MEN2-associated tumors, Genetic counseling and testing.

• #14 Multiple Endocrine Neoplasia Type 2 | St. Jude Care & Treatment

  https://www.stjude.org/care-treatment/treatment/genetic-syndromes/multiple-endocrine-neoplasia-type-2.html

  Recommended screenings for people with MEN2 include: Yearly physical exams by a health care provider who is familiar with MEN2; Yearly neck ultrasound and serum calcitonin (blood test) starting in the first few months of life to ages 35 years, depending on the RET mutation; Yearly free plasma metanephrines and normetanephrines blood work starting at 8 years old, with follow-up imaging through CT or MRI if results are abnormal; Yearly calcium and vitamin D blood work starting at 11 or 16 years old, depending on the type of RET mutation. […] People with MEN2 should avoid certain kinds of medicines. These include: Dopamine D2 receptor antagonists (such as metoclopramide and veralipride); Beta blockers; Monoamine oxidase inhibitors; Sympathomimetics (e.g., ephedrine); Certain peptide and corticosteroid hormones.

• #15 Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 2 | Oncology Nursing Society

  https://www.ons.org/publications-research/voice/news-views/08-2022/genetic-disorder-reference-sheet-multiple-endocrine

  Prior to surgery, patients with MEN2A or MEN2B should obtain biochemical screening, including measurement of catecholamine and metanephrine levels, to exclude a functioning pheochromocytoma. […] Management of MEN2 requires ongoing lifetime screening beginning in infancy. Families need psychosocial support and a consistent team of providers to implement prevention and detection measures. […] Recognizing MEN2 syndromes and referring all individuals with MTC for genetic assessment allow patients and providers to initiate screening and preventive surgery, which significantly reduces associated morbidity and mortality.

• #16 Understanding Multiple Endocrine Neoplasia Type 2: From Risk Factors to Home Remedies – The Kingsley Clinic

  https://thekingsleyclinic.com/thyroid-and-parathyroid/understanding-multiple-endocrine-neoplasia-type-2-from-risk-factors-to-home-remedies/

  Genetic testing is the gold standard for diagnosing MEN2. […] Blood tests for MEN2 measure levels of certain hormones in the bloodstream. […] These imaging tests help physicians visualize the structure of the endocrine glands and detect the presence, location, and size of any tumors. […] Thyroidectomy, the surgical removal of the thyroid gland, is the first-line treatment for MTC. […] Living with MEN2 requires an active role in managing your health. […] Regular exercise and a balanced diet can support overall health. […] Ensure regular follow-ups and screening for early detection and treatment of any new tumors. […] Multiple Endocrine Neoplasia Type 2 is a complex genetic disorder involving multiple endocrine glands. Early diagnosis and treatment are vital to managing the condition and preventing complications.

• #17 Multiple Endocrine Neoplasia Type 2 | St. Jude Care & Treatment

  https://www.stjude.org/care-treatment/treatment/genetic-syndromes/multiple-endocrine-neoplasia-type-2.html

  Recommended screenings for people with MEN2 include: Yearly physical exams by a health care provider who is familiar with MEN2; Yearly neck ultrasound and serum calcitonin (blood test) starting in the first few months of life to ages 35 years, depending on the RET mutation; Yearly free plasma metanephrines and normetanephrines blood work starting at 8 years old, with follow-up imaging through CT or MRI if results are abnormal; Yearly calcium and vitamin D blood work starting at 11 or 16 years old, depending on the type of RET mutation. […] People with MEN2 should avoid certain kinds of medicines. These include: Dopamine D2 receptor antagonists (such as metoclopramide and veralipride); Beta blockers; Monoamine oxidase inhibitors; Sympathomimetics (e.g., ephedrine); Certain peptide and corticosteroid hormones.

• #18 Multiple Endocrine Neoplasia Type 2 (MEN2) Guidelines: Guidelines Summary, Pheochromocytoma, Parathyroid Disease

  https://emedicine.medscape.com/article/123447-guidelines

  Predictive RET gene testing is the clinical standard of care for all individuals with a positive family history of MEN2 because of the very high risk of early-onset MTC in affected individuals, including children. […] The ATA guidelines recommend offering genetic counseling and genetic testing for RET germline mutations to the following individuals: First-degree relatives of patients with confirmed hereditary MTC, Parents whose infants or young children have the classic phenotype of MEN2B, Patients with cutaneous lichen amyloidosis, Infants or young children with Hirschsprung disease (HD) and exon 10 RET germline mutations, and adults with MEN2A and exon 10 mutations who have symptoms suggestive of HD. […] The ATA guidelines recommend screening for pheochromocytoma by measuring free plasma metanephrines and normetanephrines or 24-hour urinary metanephrines and normetanephrines. Adrenal imaging with CT or MRI is indicated in patients with positive biochemical results.

• #19 Multiple Endocrine Neoplasia (MEN): Types & Symptoms

  https://my.clevelandclinic.org/health/diseases/23088-multiple-endocrine-neoplasia-men

  The treatment of multiple endocrine neoplasia (MEN) depends entirely on what endocrine glands and organs are affected and usually requires a team of healthcare providers, including: Endocrinologists, Surgeons, Oncologists (cancer specialists), Pediatricians, if applicable. […] Treatment may include: Medications to treat symptoms and to counteract the effects of excess hormones, Surgery to remove tumors or entire affected glands, such as the thyroid, Replacement hormones if an endocrine gland is surgically removed, Cancer treatment, such as chemotherapy and radiation therapy, cancer has metastasized (spread to other areas of your body). […] There is currently no cure for multiple endocrine neoplasia, but it is manageable. Healthcare providers treat the changes in each gland as they happen with surgery or with medications. […] If you have been diagnosed with multiple endocrine neoplasia, you will need to see your healthcare provider regularly to monitor your condition and to see if treatment is working.

• #20 Childhood Multiple Endocrine Neoplasia (MEN) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/childhood-multiple-endocrine-neoplasia

  Multiple endocrine neoplasia (MEN) is an inherited genetic condition that causes tumors to grow in several of the body’s hormone-producing endocrine organs. MEN tumors can be benign (noncancerous) or malignant (cancerous). […] MEN type 2: MEN2 is commonly associated with medullary thyroid cancer and pheochromocytomas. MEN2 contains types 2A and 2B. Type 2A is associated with hyperparathyroidism (overactive parathyroid glands). Type 2B is linked to growths in the body’s mucosal surfaces, known as neuromas, and very early development of medullary thyroid cancer. […] We provide two programs for children with MEN1 and MEN2, including our Endocrine-Oncology Program and Boston Children’s Hospital Thyroid Center. Once in our care, we build a team to treat your child that includes pediatric experts in the areas of oncology, endocrinology, genetics, and surgery.

• #21 Multiple Endocrine Neoplasia Type 2 | Children’s Hospital of Philadelphia

  https://www.chop.edu/conditions-diseases/multiple-endocrine-neoplasia-type-2

  MEN2 is a hereditary cancer syndrome, affecting approximately 1 in 35,000 people. […] It is important to identify this hereditary cancer syndrome early, as it often confers a high risk of tumors, which may occur at a younger-than-expected age. […] Evaluation by a specialist is necessary for accurate diagnosis and treatment, including knowing when to screen and when to consider surgical treatment. […] Although there is no cure for MEN2, there are options to minimize symptoms and decrease your child’s risk of certain cancers. Early and regular screening is the most important path to allow MEN2 patients to lead happy, productive and healthy lives. […] Treatment often includes: Tumor removal, Medication. […] Since there is a high risk for individuals with MEN2 to develop MTC, and MTC is an aggressive type of thyroid cancer, preventative removal of the thyroid gland (thyroidectomy) is generally recommended for individuals with MEN2.

• #22 Multiple Endocrine Neoplasia Type 2 (MEN2) | Doctor

  https://patient.info/doctor/multiple-endocrine-neoplasia-type-2-men2

  Multiple endocrine neoplasia type 2 (MEN2) is a rare familial cancer syndrome caused by mutations in the RET proto-oncogene. […] The goals of management are: Identify individuals with germline RET-disease-causing mutations associated with MEN2 before symptoms develop. […] Reduce morbidity and mortality in the highest-risk individuals through either prophylactic thyroidectomy or screening for MTC, and through screening for phaeochromocytoma and parathyroid disease before symptoms develop. […] If the condition is confirmed then genetic counselling is required. […] Total thyroidectomy has been recommended for patients as young as 3 years for MEN2A if they contain the genetic mutation. […] In patients with the genetic mutation for MEN2B, early prophylactic total thyroidectomy is recommended. […] The most useful markers in the follow-up of MTC are plasma calcitonin and CEA.

• #23 Multiple Endocrine Neoplasia Type 2 | St. Jude Care & Treatment

  https://www.stjude.org/care-treatment/treatment/genetic-syndromes/multiple-endocrine-neoplasia-type-2.html

  Monitoring and follow-up care for MEN2 depends on how severe the disease is, the location of any tumors that may arise, and a persons overall health. Care may involve managing symptoms with medications or hormones. Patients may also have surgical removal of their tumors if the tumor presses on nearby organs or produces very high levels of hormones in their bodies. They may require other types of cancer-related treatments depending on the type of cancer they have and where it is located. […] It is recommended that children with MEN2 have surgery to remove their thyroid. […] Children with subtype 2A or the familial medullary thyroid cancer subtype: This surgery depends on several factors, including RET gene mutation, serum calcitonin levels, and what the family wants. […] Children with subtype 2B: This surgery should take place as soon as possible after the childs birth, often within the first month of life. Health care providers have found this type of thyroid cancer in very young infants.

• #24 Multiple Endocrine Neoplasia | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/multiple-endocrine-neoplasia.html

  Multiple endocrine neoplasia type 2 (MEN2) is divided into three types: MEN2A, MEN2B, and Familial Medullary Thyroid Carcinoma (FMTC). […] People with multiple endocrine neoplasia type 2 (MEN2) have a 95% chance of developing medullary thyroid cancer. […] Genetic testing of blood samples can confirm a diagnosis of MEN2 and identify family members at risk of developing the disease. […] General recommendations are to remove the thyroid gland: Within the first six months of life for individuals with MEN2B; By five to 10 years of age for individuals with MEN2A and FMTC. […] If detected early, pheochromocytomas are easily treated. However, if not treated, they may be potentially fatal due to dangerously high blood pressures that can occur during accidents, surgery, childbirth or other physically stressful situations.

• #25 Multiple Endocrine Neoplasia Type 2 | Children’s Hospital of Philadelphia

  https://www.chop.edu/conditions-diseases/multiple-endocrine-neoplasia-type-2

  After surgical removal of the thyroid gland, your child will need to take thyroid hormone replacement (one pill once daily) for the rest of their lives. […] Children diagnosed with MEN2 will need lifelong follow-up care and cancer screening. […] All patients diagnosed with MEN2 even if they have no symptoms should be screened annually for the presence of pheochromocytoma and hyperparathyroidism. […] For families that are interested, reproductive options exist for individuals with an alteration in the RET gene who do not wish to pass this alteration onto future children. […] Adults who have MEN2 or who would like more information about MEN2 may contact the Medical Genetics Team at the Hospital of the University of Pennsylvania.

• #26 Multiple Endocrine Neoplasia Type 2 (MEN2) (PDQ®) – NCI

  https://www.cancer.gov/publications/pdq/information-summaries/genetics/men2-hp-pdq

  Patients who have had total thyroidectomy require lifelong thyroid hormone replacement therapy. […] Medical therapy of hyperparathyroidism has gained popularity with the advent of calcimimetics, agents that sensitize the calcium-sensing receptors on the parathyroid glands to circulating calcium levels and thereby reduce circulating parathyroid hormone (PTH) levels. […] The psychosocial impact of genetic testing for pathogenic variants in RET has not been extensively studied. Identification as the carrier of a pathogenic variant may affect self-esteem, family relationships, and quality of life.

• #27 Multiple endocrine neoplasia 2 (MEN2) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/worried-about-cancer/pre-cancerous-and-genetic-conditions/multiple-endocrine-neoplasia-2-men2

  Your doctors will talk to you about the best way to manage any tumours. They will discuss your treatment options and explain any tests you might need to monitor your health during and after treatment. […] The main treatment for phaeochromocytoma is an operation to remove the affected adrenal gland. […] The main treatment for overactive parathyroid glands is an operation to remove some or all of the parathyroid glands. […] If the surgeon needs to remove all of your parathyroid glands, you will need to take tablets for the rest of your life. This is to control calcium levels.

• #28 Multiple Endocrine Neoplasias Type 2 – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK519054/

  First degree relatives also should be counseled for genetic testing so that they can also be provided with adequate prophylactic medical and surgical care to decrease overall morbidity and mortality. […] For MTC, the whole thyroid gland should be excised even if it is in the pre-neoplastic stage, but It is extremely necessary to perform adrenalectomy before thyroidectomy to avoid fatal complications during the surgery. […] Due to the challenges in diagnosis, treatment, and follow up a team approach involving specialty nurses, clinicians, and a pharmacist will produce the best result.

• #29 Multiple Endocrine Neoplasia Type 2 (MEN2) Guidelines: Guidelines Summary, Pheochromocytoma, Parathyroid Disease

  https://emedicine.medscape.com/article/123447-guidelines

  The ATA and NCCN guidelines recommend removal of pheochromocytoma prior to surgery for MTC or hyperparathyroidism to prevent a possible hypertensive crisis. […] The ATA guidelines include the following recommendations for the management of hyperparathyroidism in patients with MEN2A: Patients in the high and moderate risk (ATA-H and ATA-MOD) categories should be screened for hyperparathyroidism at the time of screening for pheochromocytoma, Only visibly enlarged parathyroid glands should be resected. […] Both ATA and NCCN guidelines recommend prophylactic thyroidectomy for individuals who have a documented RET mutation and are at risk for aggressive medullary thyroid carcinoma. […] Total thyroidectomy has been recommended for patients as young as 3 years for MEN2A if they contain the genetic mutation. In patients with the RET genetic mutation for MEN 2B, total thyroidectomy is recommended in infancy because medullary thyroid carcinoma behaves more aggressively in these patients. […] The extent of surgery is controversial. Total thyroidectomy with central neck dissection is recommended for all patients with proven or probable medullary thyroid carcinoma.

• #30 Multiple Endocrine Neoplasias Type 2 | Treatment & Management | Point of Care

  https://www.statpearls.com/point-of-care/25357

  Pheochromocytoma, a typically benign adrenal medullary tumor (usually bilateral and multicentric), occurs in 40% to 50% of patients with MEN2A or MEN2B; the frequency and penetration highly depend on the specific type of mutation. […] Primary hyperparathyroidism is present is 10% to 25% of patients with MEN 2A, while it is not associated with MEN 2B. […] MEN2 is a group of rare familial cancer syndrome with high penetrance and variable expressivity. Most common organs affected by this condition are endocrine glands like thyroid glands, adrenal glands and parathyroid glands among other tissues which are derived from neural crest cells. […] For MTC, the whole thyroid gland should be excised even if it is in the pre-neoplastic stage, but It is extremely necessary to perform adrenalectomy before thyroidectomy to avoid fatal complications during the surgery. […] Prior to unilateral or bilateral adrenalectomy, patients should be treated with alpha-blockade preoperatively and also should receive glucocorticoid stress coverage while awaiting transfer to the surgery.

• #31 Multiple endocrine neoplasia, type 2 (MEN 2) | Altru Health System

  https://www.altru.org/health-library/conditions/multiple-endocrine-neoplasia-type-2-men-2

  The parathyroid glands can become enlarged and make too much parathyroid hormone. The usual treatment is surgery to remove all or part of the parathyroid glands that are enlarged, while leaving any glands that are not affected. […] For these types of tumors, your health care provider will likely recommend removing one or both of the adrenal glands, depending on what is shown on the CT or MRI.

• #32 Multiple endocrine neoplasia 2 (MEN2) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/worried-about-cancer/pre-cancerous-and-genetic-conditions/multiple-endocrine-neoplasia-2-men2

  Your doctors will talk to you about the best way to manage any tumours. They will discuss your treatment options and explain any tests you might need to monitor your health during and after treatment. […] The main treatment for phaeochromocytoma is an operation to remove the affected adrenal gland. […] The main treatment for overactive parathyroid glands is an operation to remove some or all of the parathyroid glands. […] If the surgeon needs to remove all of your parathyroid glands, you will need to take tablets for the rest of your life. This is to control calcium levels.

• #33 Multiple endocrine neoplasia 2 (MEN2) | Macmillan Cancer Support

  https://www.macmillan.org.uk/cancer-information-and-support/worried-about-cancer/pre-cancerous-and-genetic-conditions/multiple-endocrine-neoplasia-2-men2

  Your doctors will talk to you about the best way to manage any tumours. They will discuss your treatment options and explain any tests you might need to monitor your health during and after treatment. […] The main treatment for phaeochromocytoma is an operation to remove the affected adrenal gland. […] The main treatment for overactive parathyroid glands is an operation to remove some or all of the parathyroid glands. […] If the surgeon needs to remove all of your parathyroid glands, you will need to take tablets for the rest of your life. This is to control calcium levels.

• #34 Multiple Endocrine Neoplasia Type 2 (MEN2) Guidelines: Guidelines Summary, Pheochromocytoma, Parathyroid Disease

  https://emedicine.medscape.com/article/123447-guidelines

  The ATA and NCCN guidelines recommend removal of pheochromocytoma prior to surgery for MTC or hyperparathyroidism to prevent a possible hypertensive crisis. […] The ATA guidelines include the following recommendations for the management of hyperparathyroidism in patients with MEN2A: Patients in the high and moderate risk (ATA-H and ATA-MOD) categories should be screened for hyperparathyroidism at the time of screening for pheochromocytoma, Only visibly enlarged parathyroid glands should be resected. […] Both ATA and NCCN guidelines recommend prophylactic thyroidectomy for individuals who have a documented RET mutation and are at risk for aggressive medullary thyroid carcinoma. […] Total thyroidectomy has been recommended for patients as young as 3 years for MEN2A if they contain the genetic mutation. In patients with the RET genetic mutation for MEN 2B, total thyroidectomy is recommended in infancy because medullary thyroid carcinoma behaves more aggressively in these patients. […] The extent of surgery is controversial. Total thyroidectomy with central neck dissection is recommended for all patients with proven or probable medullary thyroid carcinoma.

• #35 Multiple Endocrine Neoplasia Type 2 (MEN2) (PDQ®) – NCI

  https://www.cancer.gov/publications/pdq/information-summaries/genetics/men2-hp-pdq

  Patients who have had total thyroidectomy require lifelong thyroid hormone replacement therapy. […] Medical therapy of hyperparathyroidism has gained popularity with the advent of calcimimetics, agents that sensitize the calcium-sensing receptors on the parathyroid glands to circulating calcium levels and thereby reduce circulating parathyroid hormone (PTH) levels. […] The psychosocial impact of genetic testing for pathogenic variants in RET has not been extensively studied. Identification as the carrier of a pathogenic variant may affect self-esteem, family relationships, and quality of life.

• #36

  https://journals.lww.com/jfmpc/fulltext/2023/12120/multiple_endocrine_neoplasia_type_2___solving_the.64.aspx

  Multiple endocrine neoplasia type 2, which is the most common of the four types of MEN, is a hereditary syndrome characterized by pheochromocytoma, parathyroid adenomas or hyperplasia (causing hyperparathyroidism), and medullary thyroid carcinoma (MTC). MEN type 2 is inherited in an autosomal dominant manner and characterized by mutations in the RET proto-oncogene. Clinical feature of MEN type 2 depends on the affected thyroid, adrenal, and parathyroid gland. Medullary thyroid carcinoma is the most common feature and occurs in almost all individuals. MTC may present as a palpable mass in the neck, which may be asymptomatic or associated with symptoms of pressure or dysphagia, diarrhea, flushing, and ectopic ACTH production causing Cushingmon feature The diagnosis of MTC depends on serum calcitonin level of 90 pg/ml and ultrasonography of thyroid. Total thyroidectomy with systematic central neck dissection is the surgery of choice. For inoperable MTC or metastasis, tyrosine kinase receptor inhibitor like vandetanib can be used. Pheochromocytomas are adrenaline and noradrenaline secreting tumors occurs in more than 50% of MEN type 2 and are a major cause of morbidity and mortality. Blood pressure was controlled before and during surgery by alfa blockers beta blockers and calcium channel blockers. Endoscopic adrenal sparing surgery is the surgery of choice.

• #37 Multiple Endocrine Neoplasia Type 2 | St. Jude Care & Treatment

  https://www.stjude.org/care-treatment/treatment/genetic-syndromes/multiple-endocrine-neoplasia-type-2.html

  Recommended screenings for people with MEN2 include: Yearly physical exams by a health care provider who is familiar with MEN2; Yearly neck ultrasound and serum calcitonin (blood test) starting in the first few months of life to ages 35 years, depending on the RET mutation; Yearly free plasma metanephrines and normetanephrines blood work starting at 8 years old, with follow-up imaging through CT or MRI if results are abnormal; Yearly calcium and vitamin D blood work starting at 11 or 16 years old, depending on the type of RET mutation. […] People with MEN2 should avoid certain kinds of medicines. These include: Dopamine D2 receptor antagonists (such as metoclopramide and veralipride); Beta blockers; Monoamine oxidase inhibitors; Sympathomimetics (e.g., ephedrine); Certain peptide and corticosteroid hormones.

• #38 Multiple endocrine neoplasia type 2: An overview | Genetics in Medicine

  https://www.nature.com/articles/gim2011127

  Standard treatment for MTC is surgical removal of the thyroid with regional lymph node dissection. […] Prophylactic thyroidectomy is the primary preventive measure for individuals with an identified germline RET mutation. […] For all individuals with a RET mutation who have not had a thyroidectomy, annual biochemical screening is recommended with immediate thyroidectomy if results are abnormal. Annual serum calcitonin screening should begin for children with MEN 2B at age 6 months and at age 35 years for those with MEN 2A or FMTC. […] Dopamine D2 receptor antagonists (e.g., metoclopramide and veralipride) and -adrenergic receptor antagonists ( blockers) have a high potential to cause an adverse reaction in individuals with pheochromocytoma.

• #39 Multiple Endocrine Neoplasia Type 2: Diagnosis and Treatment

  https://www.massgeneral.org/children/multiple-endocrine-neoplasia-type-2/diagnosis-treatment

  How do doctors diagnose multiple endocrine neoplasia type 2 (MEN2)? […] How is MEN2 treated? […] Early and consistent screening is extremely important because many symptoms of MEN2 are not noticeable until adulthood. […] Treatment for MEN2: […] For children with MEN2 who have a higher risk of developing MTC, a thyroidectomy (removal of the thyroid gland). […] If you choose, your child can have a thyroidectomy before tumors start to develop. […] Children with MEN2 need follow-up care and screening for the remainder of their lives. […] They should also be screened every year for pheochromocytoma and hyperparathyroidism, even after removal of the thyroid gland. […] If your child has a thyroidectomy for MCT, they will need physical exams and tests every 3-6 months. […] MGfC has a very skilled team of pediatric endocrinologists and endocrine surgeons to help take care of children with MEN2 and its associated tumors. […] We provide multidisciplinary, family-centered and comprehensive care to our patients with MEN2.

• #40 Multiple endocrine neoplasia 2: providing care for the family – PubMed

  https://pubmed.ncbi.nlm.nih.gov/21112858/

  Multiple endocrine neoplasia 2 (MEN2) is a hereditary syndrome associated with medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism. […] Nurses should be familiar with hallmark signs of this syndrome to facilitate an early diagnosis and appropriately refer families for genetic assessment and, ultimately, develop a long-term plan for early detection and intervention for all family members at risk for developing MEN2. […] Multiple Endocrine Neoplasia Type 2a / nursing.

• #41 Multiple Endocrine Neoplasia 2: Providing Care for the Family | Oncology Nursing Society

  https://www.ons.org/cjon/14/6/multiple-endocrine-neoplasia-2-providing-care-family

  Multiple endocrine neoplasia 2 (MEN2) is a hereditary syndrome associated with medullary thyroid carcinoma, pheochromocytoma, and hyperparathyroidism. […] Nurses should be familiar with hallmark signs of this syndrome to facilitate an early diagnosis and appropriately refer families for genetic assessment and, ultimately, develop a long-term plan for early detection and intervention for all family members at risk for developing MEN2.

• #42 Multiple Endocrine Neoplasia Type 2 | St. Jude Care & Treatment

  https://www.stjude.org/care-treatment/treatment/genetic-syndromes/multiple-endocrine-neoplasia-type-2.html

  Recommended screenings for people with MEN2 include: Yearly physical exams by a health care provider who is familiar with MEN2; Yearly neck ultrasound and serum calcitonin (blood test) starting in the first few months of life to ages 35 years, depending on the RET mutation; Yearly free plasma metanephrines and normetanephrines blood work starting at 8 years old, with follow-up imaging through CT or MRI if results are abnormal; Yearly calcium and vitamin D blood work starting at 11 or 16 years old, depending on the type of RET mutation. […] People with MEN2 should avoid certain kinds of medicines. These include: Dopamine D2 receptor antagonists (such as metoclopramide and veralipride); Beta blockers; Monoamine oxidase inhibitors; Sympathomimetics (e.g., ephedrine); Certain peptide and corticosteroid hormones.

• #43 Multiple Endocrine Neoplasia Type 2 | Children’s Hospital of Philadelphia

  https://www.chop.edu/conditions-diseases/multiple-endocrine-neoplasia-type-2

  After surgical removal of the thyroid gland, your child will need to take thyroid hormone replacement (one pill once daily) for the rest of their lives. […] Children diagnosed with MEN2 will need lifelong follow-up care and cancer screening. […] All patients diagnosed with MEN2 even if they have no symptoms should be screened annually for the presence of pheochromocytoma and hyperparathyroidism. […] For families that are interested, reproductive options exist for individuals with an alteration in the RET gene who do not wish to pass this alteration onto future children. […] Adults who have MEN2 or who would like more information about MEN2 may contact the Medical Genetics Team at the Hospital of the University of Pennsylvania.

• #44 Multiple Endocrine Neoplasia Type 2: Diagnosis and Treatment

  https://www.massgeneral.org/children/multiple-endocrine-neoplasia-type-2/diagnosis-treatment

  How do doctors diagnose multiple endocrine neoplasia type 2 (MEN2)? […] How is MEN2 treated? […] Early and consistent screening is extremely important because many symptoms of MEN2 are not noticeable until adulthood. […] Treatment for MEN2: […] For children with MEN2 who have a higher risk of developing MTC, a thyroidectomy (removal of the thyroid gland). […] If you choose, your child can have a thyroidectomy before tumors start to develop. […] Children with MEN2 need follow-up care and screening for the remainder of their lives. […] They should also be screened every year for pheochromocytoma and hyperparathyroidism, even after removal of the thyroid gland. […] If your child has a thyroidectomy for MCT, they will need physical exams and tests every 3-6 months. […] MGfC has a very skilled team of pediatric endocrinologists and endocrine surgeons to help take care of children with MEN2 and its associated tumors. […] We provide multidisciplinary, family-centered and comprehensive care to our patients with MEN2.

• #45 MEN 2b (Multiple Endocrine Neoplasia 2b) Sippels Syndrome | Iowa Head and Neck Protocols

  https://medicine.uiowa.edu/iowaprotocols/men-2b-multiple-endocrine-neoplasia-2b-sippels-syndrome

  Multiple mucosal neuromas are a dominant feature of MEN 2b […] Management: Multidisiplinary team approach with Otolaryngology, Endocrinology, Gastroenterology, Oncology, Genetics, Social Work […] Thyroid: Total thyroidectomy with level VI (central neck) lymph node dissection before age 1 is recommended for all known MENII patients […] Patients should be followed regularly after thyroidectomy to monitor for recurrence […] 2-3 month post-op calcitonin and CEA levels. If 150pg/ml, image neck, chest and abdomen for persistent/recurrent disease […] Annual calcitonin, CEA and calcium levels […] Regular blood pressure checks.

• #46 Patient quality of life and prognosis in multiple endocrine neoplasia type 2 in: Endocrine-Related Cancer Volume 25 Issue 2 (2018)

  https://erc.bioscientifica.com/view/journals/erc/25/2/ERC-17-0335.xml

  Multiple endocrine neoplasia type 2 (MEN2) refers to the autosomal-dominant neuroendocrine tumour syndromes, MEN type 2A (MEN2A) and MEN type 2B (MEN2B). They are typified by the development of medullary thyroid cancer (MTC), phaeochromocytoma and parathyroid hyperplasia in MEN2A and MTC, phaeochromocytomas, ganglioneuromatosis and skeletal abnormalities in MEN2B. […] We recommend that these patients are cared for only in centres of expertise able to provide expert diagnosis, treatment and continuity of care, including psychological and transition support. Only in this way can the clinical advances of the last two and half decades be built upon further to ensure that the care of these complex, lifelong patients can be considered truly holistic. […] Despite all these advances, it is almost inevitable that diagnosis of a chronic complex syndrome like MEN2 will impact negatively on an individual’s quality of life, and psychological wellbeing.

• #47 Patient quality of life and prognosis in multiple endocrine neoplasia type 2 in: Endocrine-Related Cancer Volume 25 Issue 2 (2018)

  https://erc.bioscientifica.com/view/journals/erc/25/2/ERC-17-0335.xml

  The emotional impact of diagnosis depends upon a variety of factors, including the presence or absence of symptoms, other family members’ experiences of the condition, the patient’s age, cultural influences and attitudes and the capacity of healthcare professionals to break the news of the diagnosis appropriately, using sensitive language while allowing patients space to understand and absorb information. […] For most patients, any initial impact of diagnosis seems to ameliorate over time, particularly if patients have the opportunity to work through the emotional impact and meaning of the diagnosis for them as an individual. […] The capacity to remain hopeful can have an enormously positive impact on all those suffering with chronic conditions, and has been found to be a key predictor of longer survival for both breast cancer patients and HIV sufferers.

• #48 Childhood Multiple Endocrine Neoplasia (MEN) | Dana-Farber Cancer Institute

  https://www.dana-farber.org/cancer-care/types/childhood-multiple-endocrine-neoplasia

  Genetic counseling: We help your child and family cope with the stress of hereditary cancer diagnosis while discussing practical considerations such as future reproductive options. […] We also provide children with continued, comprehensive care in our pediatric cancer survivorship programs. We conduct regular medical evaluations and provide patient and family education, support groups, and counseling services. […] At Dana-Farber/Boston Children’s, your child’s care team will include specialized pediatric experts in endocrinology, medical oncology, and surgery.

• #49 Multiple Endocrine Neoplasia Type 2 (MEN2) (PDQ®) – NCI

  https://www.cancer.gov/publications/pdq/information-summaries/genetics/men2-hp-pdq

  Patients who have had total thyroidectomy require lifelong thyroid hormone replacement therapy. […] Medical therapy of hyperparathyroidism has gained popularity with the advent of calcimimetics, agents that sensitize the calcium-sensing receptors on the parathyroid glands to circulating calcium levels and thereby reduce circulating parathyroid hormone (PTH) levels. […] The psychosocial impact of genetic testing for pathogenic variants in RET has not been extensively studied. Identification as the carrier of a pathogenic variant may affect self-esteem, family relationships, and quality of life.

• #50 Patient quality of life and prognosis in multiple endocrine neoplasia type 2 in: Endocrine-Related Cancer Volume 25 Issue 2 (2018)

  https://erc.bioscientifica.com/view/journals/erc/25/2/ERC-17-0335.xml

  Patients with NETs who attend a Specialist Centre for their disease, such as a European Neuroendocrine Tumour Society (ENETS) certified Centre of Excellence, report feeling more optimistic, motivated and confident in their care, as well as more knowledgeable about their condition. […] Overall, the future is becoming much brighter for families affected by MEN2, and by studying and addressing the outstanding clinical and psychosocial needs of patients, the outlook for future care and management could soon be truly holistic.

• #51 Multiple Endocrine Neoplasia Type 2 | St. Jude Care & Treatment

  https://www.stjude.org/care-treatment/treatment/genetic-syndromes/multiple-endocrine-neoplasia-type-2.html

  It is important to seek medical help if anything unusual appears. […] People of any age with MEN2 have a higher risk of cancer. They should monitor their health and adopt healthy habits throughout life. It is important to continue to have regular physical checkups and screenings. That way, any cancer can be found early and at the most treatable stage. […] Habits that will help you maintain a healthy lifestyle include: Eat a healthy diet with lots of fruit and vegetables; Get regular exercise; Avoid excess sun exposure. Always wear a hat, protective clothing, and sunscreen (at least SPF 30 or higher) when out in the sun; Avoid unnecessary radiation exposure; Avoid smoking or the use of tobacco products; Avoid being around secondhand smoke; Avoid excessive alcohol use.

• #52 Multiple Endocrine Neoplasia Type 2 | St. Jude Care & Treatment

  https://www.stjude.org/care-treatment/treatment/genetic-syndromes/multiple-endocrine-neoplasia-type-2.html

  It is important to seek medical help if anything unusual appears. […] People of any age with MEN2 have a higher risk of cancer. They should monitor their health and adopt healthy habits throughout life. It is important to continue to have regular physical checkups and screenings. That way, any cancer can be found early and at the most treatable stage. […] Habits that will help you maintain a healthy lifestyle include: Eat a healthy diet with lots of fruit and vegetables; Get regular exercise; Avoid excess sun exposure. Always wear a hat, protective clothing, and sunscreen (at least SPF 30 or higher) when out in the sun; Avoid unnecessary radiation exposure; Avoid smoking or the use of tobacco products; Avoid being around secondhand smoke; Avoid excessive alcohol use.

• #53 Understanding Multiple Endocrine Neoplasia Type 2: From Risk Factors to Home Remedies – The Kingsley Clinic

  https://thekingsleyclinic.com/thyroid-and-parathyroid/understanding-multiple-endocrine-neoplasia-type-2-from-risk-factors-to-home-remedies/

  Genetic testing is the gold standard for diagnosing MEN2. […] Blood tests for MEN2 measure levels of certain hormones in the bloodstream. […] These imaging tests help physicians visualize the structure of the endocrine glands and detect the presence, location, and size of any tumors. […] Thyroidectomy, the surgical removal of the thyroid gland, is the first-line treatment for MTC. […] Living with MEN2 requires an active role in managing your health. […] Regular exercise and a balanced diet can support overall health. […] Ensure regular follow-ups and screening for early detection and treatment of any new tumors. […] Multiple Endocrine Neoplasia Type 2 is a complex genetic disorder involving multiple endocrine glands. Early diagnosis and treatment are vital to managing the condition and preventing complications.

• #54 Multiple endocrine neoplasia type 2A – Genomics Education Programme

  http://www.genomicseducation.hee.nhs.uk/documents/multiple-endocrine-neoplasia-type-2a/

  Multiple endocrine neoplasia type 2A (MEN2A) is an inherited condition, and a distinct subtype of multiple endocrine neoplasia type 2 (MEN2) a hereditary endocrine cancer syndrome. […] Early diagnosis, treatment and management improves outcome and quality of life for those affected by MEN2A. […] Patients with MEN2A should always be managed by a specialist multidisciplinary team, including an endocrinologist, an experienced thyroid surgeon (skilled in operating on rare medullary thyroid cancers) and a clinical geneticist/genetic counsellor. […] Annual screening is recommended by the specialist team to assess for signs of the tumours and their hormonal effects. […] Phaeochromocytoma must be removed before any other surgery undertaken. […] Patients and all blood relatives should be offered genetic counselling and RET gene testing, and children who are shown to have a RET genetic variant should undergo total thyroidectomy before they reach five years of age.

• #55 Multiple Endocrine Neoplasia (MEN): Types & Symptoms

  https://my.clevelandclinic.org/health/diseases/23088-multiple-endocrine-neoplasia-men

  The treatment of multiple endocrine neoplasia (MEN) depends entirely on what endocrine glands and organs are affected and usually requires a team of healthcare providers, including: Endocrinologists, Surgeons, Oncologists (cancer specialists), Pediatricians, if applicable. […] Treatment may include: Medications to treat symptoms and to counteract the effects of excess hormones, Surgery to remove tumors or entire affected glands, such as the thyroid, Replacement hormones if an endocrine gland is surgically removed, Cancer treatment, such as chemotherapy and radiation therapy, cancer has metastasized (spread to other areas of your body). […] There is currently no cure for multiple endocrine neoplasia, but it is manageable. Healthcare providers treat the changes in each gland as they happen with surgery or with medications. […] If you have been diagnosed with multiple endocrine neoplasia, you will need to see your healthcare provider regularly to monitor your condition and to see if treatment is working.

• #56 Multiple Endocrine Neoplasias Type 2 – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK519054/

  First degree relatives also should be counseled for genetic testing so that they can also be provided with adequate prophylactic medical and surgical care to decrease overall morbidity and mortality. […] For MTC, the whole thyroid gland should be excised even if it is in the pre-neoplastic stage, but It is extremely necessary to perform adrenalectomy before thyroidectomy to avoid fatal complications during the surgery. […] Due to the challenges in diagnosis, treatment, and follow up a team approach involving specialty nurses, clinicians, and a pharmacist will produce the best result.

• #57 Multiple Endocrine Neoplasias Type 2 – StatPearls – NCBI Bookshelf

  https://www.ncbi.nlm.nih.gov/books/NBK519054/

  Multiple endocrine neoplasia type 2 (MEN 2) is a hereditary cancer syndrome associated primarily with tumors of the adrenal gland, thyroid and parathyroid. […] This activity describes the evaluation and management of multiple endocrine neoplasia type 2 and reviews the role of the interprofessional team in improving care for patients with this condition. […] Review the use of total prophylactic thyroidectomy and lymph node dissection in the management of multiple endocrine neoplasia type 2. […] Summarize the importance of collaboration and communication among the interprofessional team to provide counseling and genetic testing to first degree relatives of those affected with multiple endocrine neoplasia type 2. […] As 25% of the patients diagnosed with Medullary thyroid cancer (MTC) have underlying RET proto-oncogene mutations, it is pertinent to screen for genetic mutations and other associated common tumors with the help of biochemical and radiological screening.

• #58 Multiple endocrine neoplasia type 2 (patient information) – wikidoc

  https://www.wikidoc.org/index.php/Multiple_endocrine_neoplasia_type_2_(patient_information)

  Multiple endocrine neoplasia (MEN) type II is a disease passed down through families, in which one or more of the endocrine glands are overactive or form a tumor. Endocrine glands most commonly involved include adrenal gland, parathyroid gland and thyroid gland. […] Multiple endocrine neoplasia type 2 cannot be cured, but regular testing can detect the problems caused by multiple endocrine neoplasia type 2. Tumors may grow for many years before serious complications develop. Surgery is indicated for thyroid tumors, adrenal tumors and parathyroid tumors. […] Screening people with family history of multiple endocrine neoplasia type 2 is recommended. […] Prognosis of the disease depends on the stage at which it is diagnosed. Early diagnosis and treatment is associated with better prognosis.

• #59 Multiple Endocrine Neoplasia Type 2 (MEN2): Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/123447-overview

  Multiple endocrine neoplasias type 2 (MEN2) is an inherited disorder characterized by the development of medullary thyroid cancer (MTC), parathyroid tumors, and pheochromocytoma. MEN2 results from germline mutations in the RET proto-oncogene and is transmitted in an autosomal dominant fashion. There are two MEN2 syndromes: MEN2A and MEN2B. […] Early total thyroidectomy remains effective in preventing the development of MTC in the long term. […] Adhering to a surveillance program lessens disease complications. Genetic counseling for the patient should be obtained, along with gene testing of the patient and family members. Screening of all first-degree relatives should be undertaken in case of genetic predisposition and reproductive options should be discussed.

• #60 Multiple endocrine neoplasia (MEN) II: MedlinePlus Medical EncyclopediaLock

  https://medlineplus.gov/ency/article/000399.htm

  Pheochromocytoma is most often not cancerous (benign). Medullary carcinoma of the thyroid is a very aggressive and potentially fatal cancer, but early diagnosis and surgery can often lead to a cure. Surgery does not cure the underlying MEN II. […] Contact your provider if you notice symptoms of MEN II or if someone in your family receives such a diagnosis. […] Screening close relatives of people with MEN II may lead to early detection of the syndrome and related cancers. This may allow for steps to prevent complications.

• #61 Multiple Endocrine Neoplasia | MD Anderson Cancer Center

  https://www.mdanderson.org/cancer-types/multiple-endocrine-neoplasia.html

  Multiple endocrine neoplasia type 2 (MEN2) is divided into three types: MEN2A, MEN2B, and Familial Medullary Thyroid Carcinoma (FMTC). […] People with multiple endocrine neoplasia type 2 (MEN2) have a 95% chance of developing medullary thyroid cancer. […] Genetic testing of blood samples can confirm a diagnosis of MEN2 and identify family members at risk of developing the disease. […] General recommendations are to remove the thyroid gland: Within the first six months of life for individuals with MEN2B; By five to 10 years of age for individuals with MEN2A and FMTC. […] If detected early, pheochromocytomas are easily treated. However, if not treated, they may be potentially fatal due to dangerously high blood pressures that can occur during accidents, surgery, childbirth or other physically stressful situations.

• #62 Multiple Endocrine Neoplasia Type 2 – Endocrine Surgery | UCLA Health

  https://www.uclahealth.org/medical-services/surgery/endocrine-surgery/patient-resources/patient-education/endocrine-surgery-encyclopedia/multiple-endocrine-neoplasia-type-2

  Diagnosis depends on identification of mutation of the RET gene. This can be done with a blood test. […] Surgery is needed to remove both the medullary carcinoma of the thyroid and the pheochromocytoma. Medullary carcinoma of the thyroid must be treated with total removal of the thyroid gland and removal of surrounding lymph nodes. Hormone replacement therapy is given after surgery. […] Family members should be screened for the RET gene mutation. […] Pheochromocytoma is usually benign (not cancer), but the accompanying medullary carcinoma of the thyroid that characterizes this condition is a very aggressive and potentially fatal cancer. Nonetheless, early diagnosis and surgery can often lead to cure. […] Screening of close relatives of a person with MEN II may lead to early detection.

• #63 Multiple Endocrine Neoplasia (MEN): Types & Symptoms

  https://my.clevelandclinic.org/health/diseases/23088-multiple-endocrine-neoplasia-men

  The treatment of multiple endocrine neoplasia (MEN) depends entirely on what endocrine glands and organs are affected and usually requires a team of healthcare providers, including: Endocrinologists, Surgeons, Oncologists (cancer specialists), Pediatricians, if applicable. […] Treatment may include: Medications to treat symptoms and to counteract the effects of excess hormones, Surgery to remove tumors or entire affected glands, such as the thyroid, Replacement hormones if an endocrine gland is surgically removed, Cancer treatment, such as chemotherapy and radiation therapy, cancer has metastasized (spread to other areas of your body). […] There is currently no cure for multiple endocrine neoplasia, but it is manageable. Healthcare providers treat the changes in each gland as they happen with surgery or with medications. […] If you have been diagnosed with multiple endocrine neoplasia, you will need to see your healthcare provider regularly to monitor your condition and to see if treatment is working.

• #64 Multiple Endocrine Neoplasia Type 2 (MEN2): Practice Essentials, Pathophysiology, Etiology

  https://emedicine.medscape.com/article/123447-overview

  Multiple endocrine neoplasias type 2 (MEN2) is an inherited disorder characterized by the development of medullary thyroid cancer (MTC), parathyroid tumors, and pheochromocytoma. MEN2 results from germline mutations in the RET proto-oncogene and is transmitted in an autosomal dominant fashion. There are two MEN2 syndromes: MEN2A and MEN2B. […] Early total thyroidectomy remains effective in preventing the development of MTC in the long term. […] Adhering to a surveillance program lessens disease complications. Genetic counseling for the patient should be obtained, along with gene testing of the patient and family members. Screening of all first-degree relatives should be undertaken in case of genetic predisposition and reproductive options should be discussed.

• #65 Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 2 | Oncology Nursing Society

  https://www.ons.org/publications-research/voice/news-views/08-2022/genetic-disorder-reference-sheet-multiple-endocrine

  Multiple endocrine neoplasia type 2 (MEN2) is an autosomal dominant disease that occurs because of germline pathogenic variants in the rearranged during transfection (RET) proto-oncogene. […] Because of their increased risk for morbidity and mortality, all patients with MTC should be offered testing for pathogenic RET variants. Those who test positive should be educated about risk-reducing thyroidectomy and other intensive screening as well as cascade testing for other family members so they can clarify their individual risk and engage in prevention and early detection measures. […] Because of the significant morbidity and mortality associated with MTC, pheochromocytoma, and parathyroid disease, prevention is the best management strategy for MEN2. […] Prophylactic thyroidectomy is recommended for individuals with an identified germline RET pathogenic variant.

• #66 Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 2 | Oncology Nursing Society

  https://www.ons.org/publications-research/voice/news-views/08-2022/genetic-disorder-reference-sheet-multiple-endocrine

  Prior to surgery, patients with MEN2A or MEN2B should obtain biochemical screening, including measurement of catecholamine and metanephrine levels, to exclude a functioning pheochromocytoma. […] Management of MEN2 requires ongoing lifetime screening beginning in infancy. Families need psychosocial support and a consistent team of providers to implement prevention and detection measures. […] Recognizing MEN2 syndromes and referring all individuals with MTC for genetic assessment allow patients and providers to initiate screening and preventive surgery, which significantly reduces associated morbidity and mortality.

• #67 Genetic Disorder Reference Sheet: Multiple Endocrine Neoplasia Type 2 | Oncology Nursing Society

  https://www.ons.org/publications-research/voice/news-views/08-2022/genetic-disorder-reference-sheet-multiple-endocrine

  Prior to surgery, patients with MEN2A or MEN2B should obtain biochemical screening, including measurement of catecholamine and metanephrine levels, to exclude a functioning pheochromocytoma. […] Management of MEN2 requires ongoing lifetime screening beginning in infancy. Families need psychosocial support and a consistent team of providers to implement prevention and detection measures. […] Recognizing MEN2 syndromes and referring all individuals with MTC for genetic assessment allow patients and providers to initiate screening and preventive surgery, which significantly reduces associated morbidity and mortality.

• #68 Patient quality of life and prognosis in multiple endocrine neoplasia type 2 in: Endocrine-Related Cancer Volume 25 Issue 2 (2018)

  https://erc.bioscientifica.com/view/journals/erc/25/2/ERC-17-0335.xml

  Patients with NETs who attend a Specialist Centre for their disease, such as a European Neuroendocrine Tumour Society (ENETS) certified Centre of Excellence, report feeling more optimistic, motivated and confident in their care, as well as more knowledgeable about their condition. […] Overall, the future is becoming much brighter for families affected by MEN2, and by studying and addressing the outstanding clinical and psychosocial needs of patients, the outlook for future care and management could soon be truly holistic.

Zobacz więcej